Table 2.
Sensitivity to Aurora inhibitors of the PC9-derived cell lines used in the study
| Cell linea | Barasertib (AURKB) IC50 (μM) | Barasertib (AURKB) % Cells | Tozasertib (AURKA, AURKB) IC50 (μM) | Tozasertib (AURKA, AURKB) % Cells | S49076 (AURKB, AXL, MET, FGFR1) IC50 (μM) | S49076 (AURKB, AXL, MET, FGFR1) % Cells |
|---|---|---|---|---|---|---|
| PC9 | 12.7 | 52 | 0.7 | 44 | >50 | 55 |
| PC9-GR1 | 13.9 | 45 | 5.7 | 65 | > 50 | 56 |
| PC9-GR2 | 30.7 | 69 | 0.5 | 47 | 1.2 | 54 |
| PC9-GR3 | 0.05 | 9 | 0.1 | 14 | 0.3 | 4 |
| PC9-GR4 | 34.4 | 67 | 7.8 | 63 | > 50 | 65 |
| PC9-GR5 | 0.04 | 37 | 0.2 | 25 | 0.9 | 33 |
| PC9-ER | 0.06 | 20 | 0.2 | 35 | 0.3 | 3 |
| PC9-GR1-AZD1 | 0.04 | 32 | 0.2 | 37 | 0.2 | 9 |
| PC9-GR1-AZD2 | 0.03 | 12 | 0.05 | 14 | 0.3 | 8 |
| PC9-GR1-AZD3 | 0.03 | 15 | 0.08 | 26 | 0.2 | 6 |
| PC9-GR1-AZD4 | 0.03 | 10 | 0.1 | 16 | 0.3 | 7 |
| PC9-GR4-AZD1 | 27.5 | 64 | 2.6 | 53 | > 50 | 57 |
| PC9-GR4-AZD2 | 23.2 | 55 | 4.6 | 50 | 0.4 | 31 |
| H1975 | > 50 | 83 | 28.8 | 84 | 22.1 | 76 |
The H1975 cell line is also included. The targets of the drugs are indicated between parentheses. The IC50s and percentage of surviving cells at 1 µM inhibitor (in MTT assays) are indicated
aIn italics, cells carrying the T790M mutation at allelic fractions > 1%